Cross-source evidence timeline
Liraglutide research timeline
Follow 167 selected, directly cited source records from March 10, 2009 through September 8, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Literature metadata
Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy.↗
PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 8, 2026 · day precisionAdded to PeptideScanner September 9, 2026Literature metadata
Treatment of obesity with liraglutide in bipolar disorder: a case report.↗
PubMed lists PMID 42597211 in Frontiers in psychiatry as Case Reports, Journal Article, with publication-date metadata of 2026-07-30 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 30, 2026 · day precisionAdded to PeptideScanner August 14, 2026Literature metadata
Application of the OBIMAP (One-Bead Interchain Multipeptide Assembly Platform) to Long Peptide Synthesis: Liraglutide as a Case Study.↗
PubMed lists PMID 41970854 in ACS omega as Journal Article, with publication-date metadata of 2026-03-25 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 25, 2026 · day precisionAdded to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT03883412↗
PeptideScanner retained ClinicalTrials.gov record NCT03883412 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 14, 2026Literature metadata
PubMed record PMID 38240127↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38240127 at 2026-08-10T10:49:06.873Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2024-01-19. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Clinical trials
ClinicalTrials.gov record NCT05313529↗
PeptideScanner retained ClinicalTrials.gov record NCT05313529 at 2026-08-13T05:52:27.020Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 14, 2026Literature metadata
PubMed record PMID 40429612↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40429612 at 2026-08-10T10:49:06.946Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-05-28. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 40913889↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40913889 at 2026-08-10T10:49:06.966Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-09-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 41321175↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41321175 at 2026-08-10T10:49:07.012Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-12-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Literature metadata
PubMed record PMID 42549609↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42549609 at 2026-08-10T10:49:12.984Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-04. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Literature metadata
PubMed record PMID 38092710↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38092710 at 2026-08-10T10:49:06.858Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-12-13. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 41651380↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41651380 at 2026-08-10T10:49:08.761Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-02-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 41736232↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41736232 at 2026-08-10T10:49:08.773Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-02-25. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 42538646↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42538646 at 2026-08-10T10:49:12.953Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 42545022↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42545022 at 2026-08-10T10:49:12.969Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 42446801↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42446801 at 2026-08-10T10:49:10.767Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-07-14. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 41508932↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41508932 at 2026-08-10T10:49:08.740Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-01-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Regulatory
Federal Register notice 2026-15285↗
The Federal Register published notice 2026-15285, attributed to FDA and its parent HHS department, on 2026-07-29. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.↗
Added to PeptideScanner August 21, 2026Literature metadata
PubMed record PMID 35936066↗
PeptideScanner retained PubMed bibliographic metadata for PMID 35936066 at 2026-08-10T18:13:32.320Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2022-08-08. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Clinical trials
ClinicalTrials.gov record NCT07225829↗
PeptideScanner retained ClinicalTrials.gov record NCT07225829 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner September 9, 2026Literature metadata
PubMed record PMID 42342869↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42342869 at 2026-08-10T18:13:52.311Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-06-24. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 42507607↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42507607 at 2026-08-10T18:13:56.762Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-27. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 42203210↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42203210 at 2026-08-10T18:13:50.682Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-05-27. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 42233323↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42233323 at 2026-08-10T18:13:50.725Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 42286095↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42286095 at 2026-08-10T18:13:52.266Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-12. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 42356253↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42356253 at 2026-08-10T18:13:53.759Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 42394413↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42394413 at 2026-08-10T18:13:53.810Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 42500463↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42500463 at 2026-08-10T18:13:56.748Z. PubMed recorded a metadata revision date of 2026-07-25 and an Entrez history date of 2026-07-25. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 40521838↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40521838 at 2026-08-10T18:13:37.865Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2025-06-16. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 42491030↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42491030 at 2026-08-10T18:13:56.726Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 41160027↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41160027 at 2026-08-10T18:13:37.970Z. PubMed recorded a metadata revision date of 2026-07-21 and an Entrez history date of 2025-10-29. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 42392029↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42392029 at 2026-08-10T18:13:53.799Z. PubMed recorded a metadata revision date of 2026-07-21 and an Entrez history date of 2026-07-02. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 42470452↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42470452 at 2026-08-10T18:13:56.686Z. PubMed recorded a metadata revision date of 2026-07-18 and an Entrez history date of 2026-07-18. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
Target-mediated drug disposition modeling of liraglutide in rats: Implications of target engagement for pharmacodynamic predictions.↗
PubMed lists PMID 41966799 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2026-04-10 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 10, 2026 · day precisionAdded to PeptideScanner August 13, 2026Literature metadata
Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio.↗
PubMed lists PMID 42442575 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2026-07-13 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 13, 2026 · day precisionAdded to PeptideScanner August 13, 2026Regulatory
Liraglutide DailyMed SPL version 6↗
DailyMed lists Structured Product Labeling version 6 for the reviewed Liraglutide label family with a published date of 2026-07-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Clinical trials
ClinicalTrials.gov record NCT04775082↗
PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026Literature metadata
Liraglutide and systolic blood pressure.↗
PubMed lists PMID 30515941 in Journal of clinical hypertension (Greenwich, Conn.) as Letter, with publication-date metadata of 2018-12-05 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 5, 2018 · day precisionAdded to PeptideScanner August 13, 2026Literature metadata
Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.↗
PubMed lists PMID 37967247 in The Journal of clinical endocrinology and metabolism as Randomized Controlled Trial, Journal Article, with publication-date metadata of 2024-04-19 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 19, 2024 · day precisionAdded to PeptideScanner August 13, 2026Regulatory
Drugs@FDA application ANDA212972↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 212972 with status AP dated 2026-07-01, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Literature metadata
Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption.↗
PubMed lists PMID 41604908 in Biomaterials advances as Journal Article, with publication-date metadata of 2026-01-14 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 14, 2026 · day precisionAdded to PeptideScanner August 13, 2026Literature metadata
PubMed record PMID 42385677↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42385677 at 2026-07-30T16:11:44.943Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-07-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Literature metadata
Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study.↗
PubMed lists PMID 39949066 in Annals of clinical and translational neurology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-02-13 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 13, 2025 · day precisionAdded to PeptideScanner August 13, 2026Literature metadata
A comprehensive analysis of community pharmacists' practices, barriers, and strategies in patient education on Saxenda®: a qualitative study.↗
PubMed lists PMID 42015323 in Journal of pharmaceutical health care and sciences as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 21, 2026 · day precisionAdded to PeptideScanner August 13, 2026Regulatory
Federal Register notice 2026-12937↗
The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.↗
Added to PeptideScanner August 21, 2026Literature metadata
Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.↗
PubMed lists PMID 38757729 in Diabetes, obesity & metabolism as Journal Article, Clinical Trial, with publication-date metadata of 2024-05-17 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: May 17, 2024 · day precisionAdded to PeptideScanner August 13, 2026Regulatory
Drugs@FDA application ANDA213155↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 213155 with status AP dated 2026-06-15, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Literature metadata
Approaching therapy of Alzheimer's disease via the antidiabetic drug liraglutide-a study with streptozotocin intracerebroventricularly treated Wistar rats.↗
PubMed lists PMID 40646278 in Journal of neural transmission (Vienna, Austria : 1996) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-07-12 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 12, 2025 · day precisionAdded to PeptideScanner August 13, 2026Literature metadata
Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus.↗
PubMed lists PMID 40914786 in Drug delivery and translational research as Journal Article, Review, with publication-date metadata of 2025-09-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 6, 2025 · day precisionAdded to PeptideScanner August 13, 2026Safety
FDA enforcement report D-0541-2026↗
FDA's dated enforcement report D-0541-2026 lists Class II and source status Ongoing for Lupin Pharmaceuticals Inc. PeptideScanner connects the report to reviewed application ANDA215421 through exact openFDA application-number annotations.↗
Added to PeptideScanner August 25, 2026Literature metadata
Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs.↗
PubMed lists PMID 38619705 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 15, 2024 · day precisionAdded to PeptideScanner August 14, 2026Literature metadata
Liraglutide in Children and Adolescents with Type 2 Diabetes.↗
PubMed lists PMID 31034184 in The New England journal of medicine as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-04-28 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 28, 2019 · day precisionAdded to PeptideScanner August 16, 2026Clinical trials
ClinicalTrials.gov record NCT04575844↗
PeptideScanner retained ClinicalTrials.gov record NCT04575844 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner September 9, 2026Regulatory
Federal Register notice 2026-08552↗
The Federal Register published notice 2026-08552, attributed to FDA and its parent HHS department, on 2026-05-01. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide and Tirzepatide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT02944500↗
PeptideScanner retained ClinicalTrials.gov record NCT02944500 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 8, 2026Clinical trials
ClinicalTrials.gov record NCT03856632↗
PeptideScanner retained ClinicalTrials.gov record NCT03856632 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 8, 2026Regulatory
FDA proposes excluding three GLP-1 ingredients from the 503B bulks list↗
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.↗
Added to PeptideScanner July 29, 2026Regulatory
Drugs@FDA application ANDA212552↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 212552 with status AP dated 2026-03-30, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Regulatory
Drugs@FDA application ANDA215245↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 215245 with status AP dated 2026-03-11, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT05965908↗
PeptideScanner retained ClinicalTrials.gov record NCT05965908 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT05681299↗
PeptideScanner retained ClinicalTrials.gov record NCT05681299 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Regulatory
Liraglutide DailyMed SPL version 3↗
DailyMed lists Structured Product Labeling version 3 for the reviewed Liraglutide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Regulatory
Drugs@FDA application ANDA217063↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 217063 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Regulatory
Drugs@FDA application ANDA217234↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 217234 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Regulatory
Drugs@FDA application ANDA217590↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 217590 with status AP dated 2026-01-14, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Safety
FDA requests removal of a warning from certain GLP-1 drug labels↗
FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels.↗
Added to PeptideScanner July 29, 2026Clinical trials
ClinicalTrials.gov record NCT06283641↗
PeptideScanner retained ClinicalTrials.gov record NCT06283641 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-09, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026
Source year
2025
Clinical trials
ClinicalTrials.gov record NCT07029009↗
PeptideScanner retained ClinicalTrials.gov record NCT07029009 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Regulatory
Federal Register notice 2025-22131↗
The Federal Register published notice 2025-22131, attributed to FDA and its parent HHS department, on 2025-12-05. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.↗
Added to PeptideScanner August 21, 2026Regulatory
Drugs@FDA application ANDA214568↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 214568 with status AP dated 2025-08-27, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Regulatory
Drugs@FDA application ANDA215421↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 215421 with status AP dated 2025-07-22, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Regulatory
Drugs@FDA application ANDA218115↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 218115 with status AP dated 2025-04-02, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT03158805↗
PeptideScanner retained ClinicalTrials.gov record NCT03158805 at 2026-07-30T18:30:10.979Z. Its registry update date was 2025-03-12, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT04881110↗
PeptideScanner retained ClinicalTrials.gov record NCT04881110 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-03, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026
Source year
2024
Regulatory
Drugs@FDA application ANDA215503↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 215503 with status AP dated 2024-12-23, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Regulatory
Federal Register notice 2024-27048↗
The Federal Register published notice 2024-27048, attributed to FDA and its parent HHS department, on 2024-11-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT04883346↗
PeptideScanner retained ClinicalTrials.gov record NCT04883346 at 2026-07-30T18:38:25.517Z. Its registry update date was 2024-11-20, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT06099067↗
PeptideScanner retained ClinicalTrials.gov record NCT06099067 at 2026-07-30T18:41:37.931Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03036800↗
PeptideScanner retained ClinicalTrials.gov record NCT03036800 at 2026-07-30T18:41:37.923Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02403284↗
PeptideScanner retained ClinicalTrials.gov record NCT02403284 at 2026-07-30T18:42:56.623Z. Its registry update date was 2024-07-22, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Regulatory
Federal Register notice 2024-10896↗
The Federal Register published notice 2024-10896, attributed to FDA and its parent HHS department, on 2024-05-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT02953665↗
PeptideScanner retained ClinicalTrials.gov record NCT02953665 at 2026-07-30T18:47:17.465Z. Its registry update date was 2024-03-07, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03672812↗
PeptideScanner retained ClinicalTrials.gov record NCT03672812 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-05, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026
Source year
2023
Clinical trials
ClinicalTrials.gov record NCT03795701↗
PeptideScanner retained ClinicalTrials.gov record NCT03795701 at 2026-07-30T19:03:45.488Z. Its registry update date was 2023-12-04, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03737240↗
PeptideScanner retained ClinicalTrials.gov record NCT03737240 at 2026-07-30T19:08:50.174Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03936049↗
PeptideScanner retained ClinicalTrials.gov record NCT03936049 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03374956↗
PeptideScanner retained ClinicalTrials.gov record NCT03374956 at 2026-07-30T19:10:42.750Z. Its registry update date was 2023-07-18, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT02527200↗
PeptideScanner retained ClinicalTrials.gov record NCT02527200 at 2026-07-30T19:10:42.748Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT04605861↗
PeptideScanner retained ClinicalTrials.gov record NCT04605861 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-07, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01779362↗
PeptideScanner retained ClinicalTrials.gov record NCT01779362 at 2026-07-30T19:13:03.753Z. Its registry update date was 2023-05-11, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02967757↗
PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026
Source year
2022
Clinical trials
ClinicalTrials.gov record NCT03479762↗
PeptideScanner retained ClinicalTrials.gov record NCT03479762 at 2026-07-30T19:32:59.846Z. Its registry update date was 2022-11-25, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT05153590↗
PeptideScanner retained ClinicalTrials.gov record NCT05153590 at 2026-07-30T19:32:59.847Z. Its registry update date was 2022-11-17, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02765399↗
PeptideScanner retained ClinicalTrials.gov record NCT02765399 at 2026-07-30T19:40:58.914Z. Its registry update date was 2022-04-12, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026
Source year
2021
Safety
FDA enforcement report D-0618-2021↗
FDA's dated enforcement report D-0618-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA206321 through exact openFDA application-number annotations.↗
Added to PeptideScanner August 25, 2026Safety
FDA enforcement report D-0622-2021↗
FDA's dated enforcement report D-0622-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA022341 through exact openFDA application-number annotations.↗
Added to PeptideScanner August 25, 2026Clinical trials
ClinicalTrials.gov record NCT02616003↗
PeptideScanner retained ClinicalTrials.gov record NCT02616003 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-23, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03466021↗
PeptideScanner retained ClinicalTrials.gov record NCT03466021 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026
Source year
2020
Clinical trials
ClinicalTrials.gov record NCT02650206↗
PeptideScanner retained ClinicalTrials.gov record NCT02650206 at 2026-07-30T20:26:41.666Z. Its registry update date was 2020-06-09, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02918279↗
PeptideScanner retained ClinicalTrials.gov record NCT02918279 at 2026-07-30T20:29:13.572Z. Its registry update date was 2020-04-27, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Regulatory
Federal Register notice 2020-04320↗
The Federal Register published notice 2020-04320, attributed to FDA and its parent HHS department, on 2020-03-03. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide and Semaglutide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT02351232↗
PeptideScanner retained ClinicalTrials.gov record NCT02351232 at 2026-07-30T20:32:04.755Z. Its registry update date was 2020-02-12, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026
Source year
2019
Clinical trials
ClinicalTrials.gov record NCT02488057↗
PeptideScanner retained ClinicalTrials.gov record NCT02488057 at 2026-07-30T20:47:16.573Z. Its registry update date was 2019-08-28, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01179048↗
PeptideScanner retained ClinicalTrials.gov record NCT01179048 at 2026-07-30T20:48:52.462Z. Its registry update date was 2019-07-17, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02060383↗
PeptideScanner retained ClinicalTrials.gov record NCT02060383 at 2026-07-30T20:52:10.194Z. Its registry update date was 2019-05-29, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02911818↗
PeptideScanner retained ClinicalTrials.gov record NCT02911818 at 2026-07-30T20:52:10.188Z. Its registry update date was 2019-05-07, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026
Source year
2018
Clinical trials
ClinicalTrials.gov record NCT02473809↗
PeptideScanner retained ClinicalTrials.gov record NCT02473809 at 2026-07-30T21:10:03.006Z. Its registry update date was 2018-09-26, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03619330↗
PeptideScanner retained ClinicalTrials.gov record NCT03619330 at 2026-07-30T21:10:02.994Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02717858↗
PeptideScanner retained ClinicalTrials.gov record NCT02717858 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-06-28, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02140983↗
PeptideScanner retained ClinicalTrials.gov record NCT02140983 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01272219↗
PeptideScanner retained ClinicalTrials.gov record NCT01272219 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-19, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026
Source year
2017
Clinical trials
ClinicalTrials.gov record NCT00422058↗
PeptideScanner retained ClinicalTrials.gov record NCT00422058 at 2026-07-30T21:22:00.247Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT00781937↗
PeptideScanner retained ClinicalTrials.gov record NCT00781937 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01557166↗
PeptideScanner retained ClinicalTrials.gov record NCT01557166 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02647944↗
PeptideScanner retained ClinicalTrials.gov record NCT02647944 at 2026-07-30T21:22:00.265Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Regulatory
Federal Register notice 2017-21202↗
The Federal Register published notice 2017-21202, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of Recombinant Deoxyribonucleic Acid Origin; Draft Guidance for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide and Teriparatide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT02321878↗
PeptideScanner retained ClinicalTrials.gov record NCT02321878 at 2026-07-30T21:23:14.758Z. Its registry update date was 2017-09-01, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT00978393↗
PeptideScanner retained ClinicalTrials.gov record NCT00978393 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01562678↗
PeptideScanner retained ClinicalTrials.gov record NCT01562678 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Regulatory
Federal Register notice 2017-10326↗
The Federal Register published notice 2017-10326, attributed to FDA and its parent HHS department, on 2017-05-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT01739049↗
PeptideScanner retained ClinicalTrials.gov record NCT01739049 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-05-04, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT00318461↗
PeptideScanner retained ClinicalTrials.gov record NCT00318461 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-03-07, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03068065↗
PeptideScanner retained ClinicalTrials.gov record NCT03068065 at 2026-07-30T21:25:36.832Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01518101↗
PeptideScanner retained ClinicalTrials.gov record NCT01518101 at 2026-07-30T21:25:36.782Z. Its registry update date was 2017-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01128894↗
PeptideScanner retained ClinicalTrials.gov record NCT01128894 at 2026-07-30T21:25:36.852Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT00873223↗
PeptideScanner retained ClinicalTrials.gov record NCT00873223 at 2026-07-30T21:25:36.788Z. Its registry update date was 2017-01-26, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01515592↗
PeptideScanner retained ClinicalTrials.gov record NCT01515592 at 2026-07-30T21:25:36.784Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01516255↗
PeptideScanner retained ClinicalTrials.gov record NCT01516255 at 2026-07-30T21:25:36.817Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01518166↗
PeptideScanner retained ClinicalTrials.gov record NCT01518166 at 2026-07-30T21:25:36.824Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01620476↗
PeptideScanner retained ClinicalTrials.gov record NCT01620476 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01507272↗
PeptideScanner retained ClinicalTrials.gov record NCT01507272 at 2026-07-30T21:25:36.818Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01507337↗
PeptideScanner retained ClinicalTrials.gov record NCT01507337 at 2026-07-30T21:25:36.779Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01508806↗
PeptideScanner retained ClinicalTrials.gov record NCT01508806 at 2026-07-30T21:25:36.763Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01620463↗
PeptideScanner retained ClinicalTrials.gov record NCT01620463 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026
Source year
2016
Clinical trials
ClinicalTrials.gov record NCT01782261↗
PeptideScanner retained ClinicalTrials.gov record NCT01782261 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-10-11, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02545738↗
PeptideScanner retained ClinicalTrials.gov record NCT02545738 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-08-10, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01237119↗
PeptideScanner retained ClinicalTrials.gov record NCT01237119 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-03-23, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Regulatory
Federal Register notice 2016-05959↗
The Federal Register published notice 2016-05959, attributed to FDA and its parent HHS department, on 2016-03-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.↗
Added to PeptideScanner August 21, 2026
Source year
2015
Literature metadata
[Basal insulin and liraglutide combined in a pen].↗
PubMed lists PMID 26364391 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2015-04 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 2015 · month precisionAdded to PeptideScanner August 14, 2026Literature metadata
New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.↗
PubMed lists PMID 20452924 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2010 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: 2010 May-Jun · source-text precisionAdded to PeptideScanner August 13, 2026Literature metadata
Liraglutide in islet transplantation: from bench to bedside.↗
PubMed lists PMID 20456108 in Transplant international : official journal of the European Society for Organ Transplantation as Comment, Journal Article, with publication-date metadata of 2010-03-01 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 1, 2010 · day precisionAdded to PeptideScanner August 13, 2026Literature metadata
Liraglutide therapy in Prader-Willi syndrome.↗
PubMed lists PMID 21388446 in Diabetic medicine : a journal of the British Diabetic Association as Case Reports, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-06 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 2011 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
[Liraglutide].↗
PubMed lists PMID 21595276 in Nihon rinsho. Japanese journal of clinical medicine as English Abstract, Journal Article, Review, with publication-date metadata of 2011-05 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: May 2011 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
[Liraglutide in the treatment of diabetes type 2].↗
PubMed lists PMID 22165195 in Lijecnicki vjesnik as English Abstract, Journal Article, Review, with publication-date metadata of 2011 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: 2011 Jul-Aug · source-text precisionAdded to PeptideScanner August 13, 2026Literature metadata
Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.↗
PubMed lists PMID 22257418 in Diabetes research and clinical practice as Case Reports, Letter, with publication-date metadata of 2012-01-16 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 16, 2012 · day precisionAdded to PeptideScanner August 13, 2026Literature metadata
[Acute pancreatitis in a patient treated with liraglutide].↗
PubMed lists PMID 23507272 in Medicina clinica as Case Reports, Letter, with publication-date metadata of 2013-03-15 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 15, 2013 · day precisionAdded to PeptideScanner August 13, 2026Literature metadata
Liraglutide in combination with acitretin for severe recalcitrant psoriasis.↗
PubMed lists PMID 23834125 in The British journal of dermatology as Case Reports, Letter, with publication-date metadata of 2013-07 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 2013 · month precisionAdded to PeptideScanner August 13, 2026Literature metadata
Acute interstitial nephritis after treatment with liraglutide.↗
PubMed lists PMID 24315766 in American journal of kidney diseases : the official journal of the National Kidney Foundation as Case Reports, Letter, with publication-date metadata of 2013-12-04 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 4, 2013 · day precisionAdded to PeptideScanner August 13, 2026Literature metadata
Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome.↗
PubMed lists PMID 25455831 in Diabetes & metabolism as Case Reports, Letter, with publication-date metadata of 2014-11-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 6, 2014 · day precisionAdded to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT01785043↗
PeptideScanner retained ClinicalTrials.gov record NCT01785043 at 2026-07-30T21:41:27.766Z. Its registry update date was 2015-09-15, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT02315001↗
PeptideScanner retained ClinicalTrials.gov record NCT02315001 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-20, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT01755572↗
PeptideScanner retained ClinicalTrials.gov record NCT01755572 at 2026-07-30T21:43:54.457Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026
Source year
2014
Regulatory
Drugs@FDA application NDA206321↗
The official Drugs@FDA dataset lists original submission 1 for NDA 206321 with status AP dated 2014-12-23, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT01507389↗
PeptideScanner retained ClinicalTrials.gov record NCT01507389 at 2026-07-30T21:54:46.547Z. Its registry update date was 2014-12-09, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT01270789↗
PeptideScanner retained ClinicalTrials.gov record NCT01270789 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026Regulatory
Federal Register notice 2014-18304↗
The Federal Register published notice 2014-18304, attributed to FDA and its parent HHS department, on 2014-08-04. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.↗
Added to PeptideScanner August 21, 2026Clinical trials
ClinicalTrials.gov record NCT01550653↗
PeptideScanner retained ClinicalTrials.gov record NCT01550653 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026
Source year
2013
Clinical trials
ClinicalTrials.gov record NCT01394341↗
PeptideScanner retained ClinicalTrials.gov record NCT01394341 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-10-09, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT01911468↗
PeptideScanner retained ClinicalTrials.gov record NCT01911468 at 2026-07-30T21:55:56.619Z. Its registry update date was 2013-07-30, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT01899430↗
PeptideScanner retained ClinicalTrials.gov record NCT01899430 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-07-15, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT01469351↗
PeptideScanner retained ClinicalTrials.gov record NCT01469351 at 2026-07-30T21:55:56.623Z. Its registry update date was 2013-04-19, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026
Source year
2012
Clinical trials
ClinicalTrials.gov record NCT01695109↗
PeptideScanner retained ClinicalTrials.gov record NCT01695109 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-09-27, and PeptideScanner's reviewed identity mapping was liraglutide.↗
Added to PeptideScanner August 13, 2026Regulatory
Federal Register notice 2012-10517↗
The Federal Register published notice 2012-10517, attributed to FDA and its parent HHS department, on 2012-05-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.↗
Added to PeptideScanner August 21, 2026Literature metadata
PubMed record PMID 20610447↗
PeptideScanner retained PubMed bibliographic metadata for PMID 20610447 at 2026-07-30T22:15:26.499Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-07-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026
Source year
2010
Literature metadata
PubMed record PMID 20861602↗
PeptideScanner retained PubMed bibliographic metadata for PMID 20861602 at 2026-07-30T22:26:16.803Z. PubMed recorded a metadata revision date of 2010-09-23 and an Entrez history date of 2010-09-24. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Regulatory
Drugs@FDA application NDA022341↗
The official Drugs@FDA dataset lists original submission 1 for NDA 022341 with status AP dated 2010-01-25, and names liraglutide among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026
Source year
2009
Regulatory
Federal Register notice E9-5024↗
The Federal Register published notice E9-5024, attributed to FDA and its parent HHS department, on 2009-03-10. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.↗
Added to PeptideScanner August 21, 2026